Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 4, 2013, Pages 327-336

  Braun, Thorsten ^a   Fenaux, Pierre ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

AML; autoimmunity; CMML; MDS; Treg

Indexed keywords

ANTINUCLEAR ANTIBODY; CYTOKINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BEHCET DISEASE; CELL FUNCTION; CELLULAR IMMUNITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOKINE RELEASE; CYTOPENIA; CYTOTOXICITY; DEREGULATION; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHEMA; HELPER CELL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL PARAMETERS; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POLYARTHRITIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REGULATORY T LYMPHOCYTE; RELAPSING POLYCHONDRITIS; REVIEW; RHEUMATOID ARTHRITIS; VASCULITIS;

AML; AUTOIMMUNITY; CMML; MDS; TREG;

ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSION; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MYELODYSPLASTIC SYNDROMES; MYELOID PROGENITOR CELLS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893811075     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.09.003     Document Type: Review

References (82)

1. S. Berthier, N. Magy, and H. Gil et al. Myelodysplasies et maladies systémiques: une association non fortuite Rev Med Interne 22 2001 428 432
2. H. Enright, H.S. Jacob, and G. Vercellotti et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy Br J Haematol 91 1995 403 408
3. A. de Hollanda, A. Beucher, and D. Henrion et al. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study Arthritis Care Res (Hoboken) 63 2011 1188 1194
4. E. Reinhold Keller, N. Beuge, and U. Latza et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long term outcome in 155 patients Arthritis Rheum 43 2000 1021 1032
5. C.J. McCarthy, S. Sheldon, and C.W. Ross et al. Cytogenetic abnormalities and therapy related myelodysplastic syndromes in rheumatic disease Arthritis Rheum 41 1998 1493 1496
6. E.M. Sloand, L. Mainwaring, and M. Fuhrer et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome Blood 106 2005 841 851
7. E.M. Sloand, C.O. Wu, and P. Greenberg et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy J Clin Oncol 26 2008 2505 2511
8. E.M. Sloand, J.J. Melenhorst, and Z.C. Tucker et al. T cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy Blood 117 2011 2691 2699
9. E.M. Sloand, M.J. Olnes, and A. Shenoy et al. Alemtuzumab treatment of intermediate 1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions J Clin Oncol 28 2010 5166 5173
10. Z.Y. Lim, S. Killick, and U. Germing et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin Leukemia 21 2007 1436 1441
11. L.A. Anderson, R.M. Pfeiffer, and O. Landgren et al. Risks of myeloid malignancies in patients with autoimmune conditions Br J Cancer 100 2009 822 828
12. A.W. Mailloux, C. Sugimori, and R.S. Komrokji et al. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome J Immunol 189 2012 3198 3208
13. M.A. Hamidou, S. Derenne, and M.A. Audrain et al. Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study Rheumatology 39 2000 417 420
14. S. Kimura, J. Kuroda, and T. Akaogi et al. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis Behcet's syndrome Leuk Lymphoma 42 2001 115 121
15. K. Becker, O. Fitzgerald, and A.J. Green et al. Constitutional trisomy 8 and Behçet syndrome Am J Med Genet A 149A 2009 982 986
16. S. Giannouli, D. Tzoanopoulos, and K. Ritis et al. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor 1 (IRF 1) expression Ann Rheum Dis 63 2004 578 582
17. O. Fain, J. Paries, and M. Hamidou et al. Vasculitides and cancers: 60 cases Arthritis Rheum 50 2004 S436
18. M.A. Hamidou, A. Boumalassa, and C. Larroche et al. Systemic medium size vessel vasculitis associated with chronic myelomonocytic leukaemia Semin Arthritis Rheum 31 2001 119 126
19. Y.C. Lin, T.H. Liang, and H.N. Chang et al. Behçet disease associated with myelodysplastic syndrome J Clin Rheumatol 14 2008 169 174
20. T. Shigemura, K. Agematsu, and T. Yamazaki et al. A case of Behcet's disease associated with myelodysplastic syndrome involving trisomy 8 and a gain of function mutation in SHP 2 Rheumatology (Oxford) 50 2011 1342 1344
21. J.K. Ahn, H.S. Cha, and E.M. Koh et al. Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8 Rheumatology (Oxford) 47 2008 1228 1230
22. B. Ladizinski, E.J. Shannon, and M.R. Sanchez et al. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders J Drugs Dermatol 9 2010 814 826
23. F. Baron, S. Suciu, and S. Amadori et al. Value of infliximab (Remicade(R)) in patients with low risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group Haematologica 97 2012 529 533
24. S.W. George, and E.D. Newman Seronegative inflammatory arthritis in the myelodysplastic syndromes Semin Arthritis Rheum 21 1992 345 354
25. I. Pajus, and B. Amor Manifestations rhumatologiques associées aux syndromes myélodysplasiques et myéloprolifératifs Rev Rhum Mal Osteoartic 59 1992 11 16
26. G. Espinosa, J. Font, and F.J. Munoz Rodriguez et al. Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship? Clin Rheumatol 21 2002 309 313
27. C.C. Mok, C.S. Lau, and C.R. Kumana Polymyalgia rheumatica as the rheumatological manifestation of myelodysplastic syndrome in a Chinese patient Br J Rheumatol 35 1996 496 497
28. E. Rizos, G. Dimos, and H.J. Milionis et al. Temporal arteritis masquerading as chronic myelomonocytic leukemia Clin Exp Rheumatol 21 2003 685 686
29. M.D. Vignon Pennamen, C. Juillard, and M. Rybojad et al. Chronic recurrent lymphocytic sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases Arch Dermatol 142 2006 1170 1176
30. D. Kroshinsky, M.P. Hoang, and R.P. Hasserjian Case records of the Massachusetts General Hospital. Case 1 2012. An 82 year old man with persistent ulcers on the hands N Engl J Med 366 2012 166 174
31. P.R. Cohen, and R. Kurzrock Sweet's syndrome and malignancy Am J Med 82 1987 1220 1226
32. C.E. Browning, J.E. Dixon, and J.C. Malone et al. Thalidomide in the treatment of recalcitrant Sweet's syndrome associated with myelodysplasia J Am Acad Dermatol 53 2 Suppl. 1 2005 S135 S138
33. M.A. Reuss Borst, G. Pawelec, and J.G. Saal et al. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease Br J Haematol 84 1993 356 358
34. X. Feng, P. Scheinberg, and C.O. Wu et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes Haematologica 96 2011 602 606
35. D. Aldinucci, D. Poletto, and P. Nanni et al. CD40L induces proliferation, self renewal, rescue from apoptosis, and production of cytokines by CD40 expressing AML blasts Exp Hematol 30 2002 1283 1292
36. S. Paydas, B. Sahin, and E. Seyrek et al. Sweet's syndrome associated with G CSF Br J Haematol 85 1993 191 192
37. A. Delluc, N. Limal, and X. Puéchal et al. Efficacy of anakinra, an IL1 receptor antagonist, in refractory sweet syndrome Ann Rheum Dis 67 2008 278 279
38. T. Yamauchi, K. Ishida, and Y. Iwashima et al. Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome J Infect Chemother 9 2003 268 271
39. S. Aractingi, C. Bachmeyer, and H. Dombret et al. Simultaneous occurrence of two rare cutaneous markers of poor prognosis in myelodysplastic syndrome: erythema elevatum diutinum and specific lesions Br J Dermatol 131 1994 112 117
40. M. Hebbar, M. Brouillard, and E. Wattel et al. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence Leukemia 9 1995 731 733
41. C.J. Michet Jr., C.H. McKenna, and H.S. Luthra et al. Relapsing polychondritis. Survival and predictive role of early disease manifestations Ann Intern Med 104 1986 74 78
42. J.C. Piette, T. Papo, and P. Chavanon et al. Myelodysplasia and relapsing polychondritis J Rheumatol 22 1995 1208 1209
43. C.C. Lai, Y.S. Chang, and K.H. Hsiao et al. Relapsing polychondritis associated refractory airway stenosis J Rheumatol 38 2011 2488 2489
44. T. Saitoh, H. Murakami, and H. Uchiumi et al. Myelodysplastic syndromes with nephrotic syndrome Am J Hematol 60 1999 200 204
45. C. Eng, F.A. Farraye, and L.N. Shulman et al. The association between the myelodysplastic syndromes and Crohn disease Ann Intern Med 117 1992 661 662
46. Y. Xue, Y. Han, and T. Li et al. Pulmonary alveolar proteinosis as a terminal complication in a case of myelodysplastic syndrome with idic (20q) Acta Haematol 123 2010 55 58
47. A.A. Giagounidis, S. Haase, and U. Germing et al. Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion Acta Haematol 113 2005 146 149
48. S.J. Park, C.W. Han, and J.H. Lee et al. Cyclosporine A in the treatment of a patient with immune thrombocytopenia accompanied by myelodysplastic syndrome and nephrotic syndrome Acta Haematol 110 2003 36 40
49. E. Bourgeois, M.T. Caulier, and C. Rose et al. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases Leukemia 15 2001 950 953
50. S.Y. Kordasti, W. Ingram, and J. Hayden et al. CD4+CD25+high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS) Blood 110 2007 847 850
51. J.P. Maciejewski Immune mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones Folia Histochem Cytobiol 45 2007 5 14
52. T.J. Hamblin Immunological abnormalities in myelodysplastic syndromes Semin Hematol 33 1996 150 162
53. K.J. Kim, S.K. Kwok, and Y.J. Park et al. Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis Int J Rheum Dis 15 2012 86 94
54. Y.E. Claessens, D. Bouscary, and J.M. Dupont et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for fas dependent apoptosis Blood 99 2002 1594 1601
55. W. Zeng, A. Miyazato, and G. Chen et al. Interferon gamma induced gene expression in CD34 cells: identification of pathologic cytokine specific signature profiles Blood 107 2006 167 175
56. T. Braun, G. Carvalho, and A. Coquelle et al. NF kappaB constitutes a potential therapeutic target in high risk myelodysplastic syndrome Blood 107 2006 1156 1165
57. J. Maciejewski, C. Selleri, and S. Anderson et al. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine mediated hematopoietic suppression in vitro Blood 85 1995 3183 3190
58. A. Boula, M. Voulgarelis, and S. Giannouli et al. Effect of cA2 anti tumor necrosis factor alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes Clin Cancer Res 12 2006 3099 3108
59. A. Verma, and A.F. List Cytokine targets in the treatment of myelodysplastic syndromes Curr Hematol Rep 4 2005 429 435
60. M. Lazarini, F. Traina, and S.M. Winnischofer et al. Effects of thalidomide on long term bone marrow cultures from patients with myelodysplastic syndromes: induction of IL 10 expression in the stromal layers Leuk Res 35 2011 1102 1107
61. D.Y. Zang, R.G. Goodwin, and M.R. Loken et al. Expression of tumor necrosis factor related apoptosis inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis Blood 98 2001 3058 3065
62. L. Zhou, A.N. Nguyen, and D. Sohal et al. Inhibition of the TGF beta receptor I kinase promotes hematopoiesis in MDS Blood 112 2008 3434 3443
63. D.M. Kerbauy, V. Lesnikov, and N. Abbasi et al. NF kappaB and FLIP in arsenic trioxide (ATO) induced apoptosis in myelodysplastic syndromes (MDSs) Blood 106 2005 3917 3925
64. I. Baumann, C. Scheid, and M.S. Koref et al. Autologous lymphocytes inhibit haemopoiesis in long term culture in patients with myelodysplastic syndrome Exp Hematol 30 2002 1405 1411
65. A. Sternberg, S. Killick, and T. Littlewood et al. Evidence for reduced B cell progenitors in early (low risk) myelodysplastic syndrome Blood 106 2005 2982 2991
66. G. Ruggiero, M. Sica, and L. Luciano et al. A case of myelodysplastic syndrome associated with CD14(+)CD56(+) monocytosis, expansion of NK lymphocytes and defect of HLA E expression Leuk Res 33 2009 181 185
67. B. Costantini, S. Kordasti, and A.G. Kulasekararaj et al. The effects of 5 azacytidine on the function and number of regulatory T cells and T effectors in myelodysplastic syndrome Haematologica 98 2013 1196 1205
68. + regulatory T cells in myelodysplastic syndromes (MDS) Leukemia 23 2009 510 518
69. S.Y. Kordasti, B. Afzali, and Z. Lim et al. IL 17 producing CD4(+) T cells, pro inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome Br J Haematol 145 2009 64 72
70. J.J. Kiladjian, G. Visentin, and E. Viey et al. Activation of cytotoxic T cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes Haematologica 93 3 2008 381 389
71. J.J. Kiladjian, E. Bourgeois, and I. Lobe et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes Leukemia 20 2006 463 470
72. P.K. Epling Burnette, F. Bai, and J.S. Painter et al. Reduced natural killer (NK) function associated with high risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors Blood 109 2007 4816 4824
73. A.C. Chan, P. Neeson, and E. Leeansyah et al. Testing the NKT cell hypothesis in lenalidomide treated myelodysplastic syndrome patients Leukemia 24 2010 592 600
74. T. Shimamoto, and K. Ohyashiki Immunosuppressive treatments for myelodysplastic syndromes Leuk Lymphoma 44 2003 593 604
75. J.J. Molldrem, M. Caples, and D. Mavroudis et al. Antithymocyte globulin for patients with myelodysplastic syndrome Br J Haematol 99 1997 699 705
76. J.R. Passweg, A.A. Giagounidis, and M. Simcock et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care SAKK 33/99 J Clin Oncol 29 2011 303 309
77. A. Raza, A. Candoni, and U. Khan et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes Leuk Lymphoma 45 2004 2099 2104
78. A. List, G. Dewald, and J. Bennett et al. Myelodysplastic Syndrome 003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 2006 1456 1465
79. A. Raza, J.A. Reeves, and E.J. Feldman et al. Phase 2 study of lenalidomide in transfusion dependent, low risk, and intermediate 1 risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood 111 2008 86 93
80. L. Adès, S. Boehrer, and T. Prebet et al. Efficacy and safety of lenalidomide in intermediate 2 or high risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study Blood 113 2009 3947 3952
81. R. Invernizzi, E. Travaglino, and M. De Amici et al. Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes Leuk Res 29 2005 641 647
82. C.Y. Chung, S.F. Lin, and P.M. Chen et al. Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: results of a phase II trial Anticancer Res 32 2012 3415 3419